Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21330986 | 1.00 | ADORA2A (0.72) | ADORA2A | |
| SCHEMBL21833481 | 0.90 | ADORA2A (0.59) | ADORA2A | |
| SCHEMBL24445775 | 0.89 | ADORA2A (0.77) | ADORA2A | |
| SCHEMBL24446021 | 0.89 | ADORA2A (0.75) | ADORA2A | |
| SCHEMBL29755460 | 0.89 | ADORA2A (0.70) | ADORA2A | |
| SCHEMBL20521557 | 0.89 | ADORA2A (0.70) | ADORA2A | |
| SCHEMBL25541278 | 0.88 | ADORA2A (0.74) | ADORA2A | |
| SCHEMBL20521505 | 0.88 | ADORA2A (0.77) | ADORA2A | |
| SCHEMBL21887098 | 0.88 | ADORA2A (0.75) | ADORA2A | |
| SCHEMBL24445996 | 0.87 | ADORA2A (0.72) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4135703-A1 | METHODS AND FORMULATIONS FOR ADMINISTRATION OF THIOCARBAMATE DERIVATIVES A2A INHIBITORS | iTeos Belgium SA (BE) | 2023-02-22 | — | — | EP | claimed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | disclosed |
| WO-2024194392-A1 | MULTICOMPONENT COMPLEXES, INCLUDING SALTS AND CRYSTALLINE COMPLEXES, OF ENT1 INHIBITORS | iTeos Belgium SA (BE) | 2024-09-26 | — | — | WO | disclosed |
| WO-2024134541-A1 | HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240141436-A1 | Compounds, Compositions and Methods of Treatment Thereof | iTeos Belgium SA (BE) | 2024-05-02 | — | — | US | disclosed |
| WO-2024040036-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF DISEASE ASSOCIATED WITH EXPRESSION OF AT LEAST ONE ANTIBODY-SECRETING CELL MARKER | iTeos Belgium SA (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4294948-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT THEREOF | iTeos Belgium SA (BE) | 2023-12-27 | — | — | EP | disclosed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230165863-A1 | METHODS AND FORMULATIONS FOR ADMINISTRATION OF THIOCARBAMATE DERIVIATIVES A2A INHIBITORS | iTeos Belgium SA (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2023-05-25 | — | — | US | disclosed |
| US-20230121530-A1 | THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND COMBINATIONS WITH ANTICANCER AGENTS | iTeos Belgium SA (BE) | 2023-04-20 | — | — | US | disclosed |
| EP-4135703-A1 | METHODS AND FORMULATIONS FOR ADMINISTRATION OF THIOCARBAMATE DERIVATIVES A2A INHIBITORS | iTeos Belgium SA (BE) | 2023-02-22 | — | — | EP | disclosed |
| EP-4132933-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-02-15 | — | — | EP | disclosed |
| EP-4110784-A1 | PYRIMIDO[5,4-D]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022178135-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT THEREOF | ITEOS BELGUIM SA (US) | 2022-08-25 | — | — | WO | disclosed |
| US-11376255-B2 | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents | iTeos Belgium SA (BE) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376255-B2 | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885 |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | ADORA2A 10/4885 |
| US-20230165863-A1 | METHODS AND FORMULATIONS FOR ADMINISTRATION OF THIOCARBAMATE DERIVIATIVES A2A INHIBITORS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885 |
| US-20240141436-A1 | Compounds, Compositions and Methods of Treatment Thereof | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885 |
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885 |
| US-20230121530-A1 | THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND COMBINATIONS WITH ANTICANCER AGENTS | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.